

IN THE CLAIMS

The status of each claim is listed below.

Claims 1-20: Canceled.

21. (New) A method of suppressing a rejection of an organ transplant rejection, comprising administering to an organ transplant recipient an effective amount a composition comprising a substance having a function of decreasing a reduced glutathione content in at least one cell selected from the group consisting of macrophages, monocytes and dendric cells.

22. (New) The method according to claim 21, wherein the substance can reduce the glutathione content by at least 30% when incubated in vitro with macrophages for from 1 to 24 hours.

23. (New) The method according to claim 21, wherein the substance the substance has the function of decreasing a reduced glutathione content in macrophages.

24. (New) The method according to claim 21, wherein the substance the substance has the function of decreasing a reduced glutathione content in monocytes.

25. (New) The method according to claim 21, wherein the substance the substance has the function of decreasing a reduced glutathione content in dendric cells.

26. (New) The method according to claim 21, wherein the substance is at least one member selected from the group consisting of a N, N'-diacylcystine, N, N'-diacylcystine ester, busulfan, L-S, R-buthionine sulfoximine, R-buthionine sulfoximine derivative and a maleic acid diester.

27. (New) The method according to claim 21, wherein the substance is N, N'-diacylcystine.

28. (New) The method according to claim 21, wherein the organ is at least one member selected from the group consisting of liver, lung, kidney, liver, heart, skin, cornea, and corneal epithelium.

29. (New) The method according to claim 21, wherein the organ is a part of at least one member selected from the group consisting of liver, lung, kidney, liver, heart, skin, cornea, and corneal epithelium.

30. (New) The method according to claim 21, wherein the organ is at least one member selected from the group consisting of a cornea and corneal epithelium.

31. (New) The method according to claim 21, wherein the organ is corneal epithelium.

32. (New) The method according to claim 21, wherein the rejection is mainly a rejection to a minor antigen.

33. (New) The method according to claim 21, wherein the composition is in the form of an oral drug, eye drop or infusion.

34. (New) The method according to claim 21, wherein the organ transplant recipient is a mammal.

35. (New) The method according to claim 21, wherein the organ transplant recipient is a human.

36. (New) The method according to claim 21, wherein the substance is administered in at least one form selected from the group consisting of an oral drug, eye drop and infusion.

37. (New) The method according to claim 21, wherein the substance is administered in at least one form selected from the group consisting of a pharmaceutical, food, drink and nutriment.

38. (New) The method according to claim 21, wherein the composition is administered at a dose ranging from at least once a day to at least once every 5 days.

39. (New) The method according to claim 21, wherein the composition is administered at a dose ranging from 1 mg to 10 g.